+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 75Years
All Genders
ID07497165

Real-World Study of Epunamin Combined With DECP Regimen for Adults with Relapsed or Refractory Multiple Myeloma

Led by Shanxi Bethune Hospital · Updated on 2026-03-27

48

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of Epunamin combined with a DECP-based regimen for patients with relapsed or refractory multiple myeloma, a type of blood cancer that remains incurable despite current treatments. This observational study aims to assess the effectiveness and safety of this combination in a real-world clinical setting. The study includes adult patients aged 18 to 75 years who have previously received at least one systemic treatment for their condition. Participants will receive Epunamin along with a DECP-based regimen consisting of Cisplatin, Etoposide, Cyclophosphamide, and Dexamethasone in 28-day cycles. The dosing schedule includes Epunamin administered on specific days, with a step-up dosing approach for some patients, especially those with a high tumor burden or bulky disease. The study plans for patients to receive at least four to six cycles of treatment, with preventive measures for blood clots during therapy. During the study, researchers will monitor patients regularly to assess treatment responses, including overall response rate after four cycles. They will also evaluate other outcomes such as very good partial response, complete response, minimal residual disease, and time to next treatment. Safety and side effects will be tracked, and statistical methods will be used to analyze survival and treatment effectiveness. Patient enrollment and follow-up will take place from October 2025 to September 2027.

CONDITIONS

Brief Title

Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma

Research Team

T

Tian Weiwei Tian Weiwei, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here